Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Rexahn initiates phase IIa clinical trial of Serdaxin in major depressive disorder

Feb. 3, 2009

Supernus initiates phase IIa SPN-810 trial in conduct disorder

Feb. 2, 2009

BioMS Medical reports results of exploratory phase II dirucotide trial in MS

Feb. 2, 2009

GSK claims new CGRP receptor antagonists useful for treating migraine and cluster headache

Feb. 2, 2009

Novel sodium channel blockers with analgesic activity developed at AstraZeneca

Feb. 2, 2009

Kv1 potassium channel inhibitors with anxiolytic properties synthesized at Lectus Therapeutics

Feb. 2, 2009

Acrux ceases development of Fentanyl MDTS for chronic pain

Jan. 30, 2009

Cannasat to commence phase Ib CAT-310 study for neuropathic pain

Jan. 30, 2009

Connexin43 mimetic peptide shows promise in spinal cord contusion injury model

Jan. 30, 2009

Roche divulges antipsychotic tachykinin NK3 receptor antagonists

Jan. 30, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.